By: Dr. Elton Gómez, specialist in stem cells.
Since 1988, there has been experiments with placental implantation, which was applied anecdotally, for the treatment of diabetic patients and patients with rheumatoid arthritis, with the approval of the use of metformin in 1995 by the American authorities to treat diabetes, the investigation fell into oblivion, only recently has it been possible to resume this important therapy to treat and reverse diabetes mellitus and rheumatoid arthritis.
In the research carried out in experimental animals, in which diabetes is stimulated with an injection of a chemical substance, and after the placentotherapy is applied, the results speak for themselves, the implant of the placenta had a shocking effect, in the evolution of the disease, it reversed in most cases, the complication in some specimens was infection, which hindered its use in humans.
But recently, with the use of a purified, clean and sterilized extract of placental proteins, the problem has gone down in history.
The Mexican Institute of Social Security (IMSS) has conducted extensive research in the most specialized Mexican research centers, such as the immunobiology laboratory, in order to minimize the risks for these patients, and maximize the benefits of placentotherapy.
The chemical markers of diabetes, (TLR2, and TRL4) and substances such as Interleukin 6, and TNF alpha, mediators of inflammation in Arthritis, have shown decisive improvements, not only in experimental animals, but in human patients who volunteered for the study.
Soon this and other health institutions will place this new placental protein implant treatment (IPP) available to their beneficiaries, while several private clinics are already offering this novel and very effective treatment to control diabetes mellitus and rheumatoid arthritis.